DCGI States Pholcodine Containing Cough Syrups Pose Safety Concerns

DCGI States Pholcodine Containing Cough Syrups Pose Safety Concerns

The World Health Organization (WHO) has warned healthcare professionals and regulatory authorities about the risk of anaphylactic reactions due to cough syrups and cold remedies containing pholcodine. Those taking these medications at least 12 months before undergoing surgical procedures with general anesthesia and neuromuscular blocking agents (NMBAS) are at greater risk.

In response to the WHO alert, the Drugs Controller General of India (DCGI), Rajeev Raghuvanshi, has issued an advisory for doctors, medical professionals, and patients who have used or have been using pholcodine containing cough syrups and cold remedies. The DCGI recommends that individuals discontinue using such cough syrups and seek alternative treatments for their symptoms.

The matter has been referred to the Subject Expert Committee (Antimicrobial & Antiviral) to seek expert opinion on the safety concern raised by the WHO. The DCGI urges doctors to inquire whether patients scheduled for general anesthesia containing NMBAS have taken pholcodine-containing cough syrups in the past 12 months and be vigilant about anaphylactic reactions in such cases.

Patients should be cautious when using cough syrups with pholcodine and consult their doctors and pharmacists for alternative treatments. Those who have taken such cough syrups in the last 12 months and are scheduled for general anesthesia should inform their doctors before the procedure.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks